Aileron Therapeutics Inc (NASDAQ:ALRN) Director Rickenbach Josef H. Von Acquires 28,466 Shares
Aileron Therapeutics Inc (NASDAQ:ALRN) Director Rickenbach Josef H. Von purchased 28,466 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were purchased at an average price of $0.72 per share, for a total transaction of $20,495.52. Following the completion of the purchase, the director now directly owns 68,352 shares of the company’s stock, valued at $49,213.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NASDAQ ALRN traded up $0.04 during mid-day trading on Friday, hitting $0.82. The company had a trading volume of 264,736 shares, compared to its average volume of 269,559. The company has a market capitalization of $21.69 million, a PE ratio of -0.40 and a beta of 2.31. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.04 and a quick ratio of 6.04. Aileron Therapeutics Inc has a 1-year low of $0.44 and a 1-year high of $3.55. The business’s 50-day simple moving average is $0.61 and its 200 day simple moving average is $1.18.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, analysts expect that Aileron Therapeutics Inc will post -1.14 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Aileron Therapeutics by 179.6% in the second quarter. BlackRock Inc. now owns 49,485 shares of the company’s stock valued at $36,000 after acquiring an additional 31,787 shares in the last quarter. Deutsche Bank AG raised its stake in shares of Aileron Therapeutics by 432.9% in the fourth quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock valued at $108,000 after acquiring an additional 104,932 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Aileron Therapeutics by 261.6% in the second quarter. Vanguard Group Inc. now owns 333,005 shares of the company’s stock valued at $240,000 after acquiring an additional 240,910 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Aileron Therapeutics by 649.6% in the first quarter. Jennison Associates LLC now owns 2,040,255 shares of the company’s stock valued at $3,828,000 after acquiring an additional 1,768,073 shares in the last quarter. Institutional investors and hedge funds own 23.05% of the company’s stock.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Further Reading: What is the Stochastic Momentum Index (SMI)?
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.